Oscar Health (NYSE:OSCR) Trading Up 5.9%

Shares of Oscar Health, Inc. (NYSE:OSCR) were up 5.9% on Tuesday . The stock traded as high as $14.29 and last traded at $14.29. Approximately 764,232 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 3,389,728 shares. The stock had previously closed at $13.50.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on OSCR shares. Raymond James started coverage on Oscar Health in a research note on Friday, March 22nd. They issued an “outperform” rating and a $20.00 price target for the company. TheStreet upgraded Oscar Health from a “d” rating to a “c-” rating in a research report on Wednesday, February 21st. The Goldman Sachs Group upped their price objective on Oscar Health from $8.00 to $16.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Finally, Wells Fargo & Company boosted their price target on Oscar Health from $12.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $13.50.

Oscar Health Stock Performance

The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.37. The firm has a 50 day moving average of $14.59 and a 200-day moving average of $9.79. The company has a market cap of $3.26 billion, a P/E ratio of -11.85 and a beta of 1.82.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Wednesday, February 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08. The business had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Oscar Health had a negative return on equity of 29.99% and a negative net margin of 4.62%. The company’s revenue for the quarter was up 43.9% compared to the same quarter last year. During the same period last year, the firm earned ($1.05) earnings per share. As a group, sell-side analysts anticipate that Oscar Health, Inc. will post -0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Oscar Health

Several large investors have recently bought and sold shares of the business. Voya Investment Management LLC increased its holdings in Oscar Health by 1.7% in the fourth quarter. Voya Investment Management LLC now owns 62,955 shares of the company’s stock valued at $576,000 after buying an additional 1,064 shares during the last quarter. American International Group Inc. grew its holdings in shares of Oscar Health by 1.6% during the fourth quarter. American International Group Inc. now owns 78,402 shares of the company’s stock worth $717,000 after purchasing an additional 1,199 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Oscar Health by 10.6% during the third quarter. Amalgamated Bank now owns 15,762 shares of the company’s stock worth $88,000 after purchasing an additional 1,516 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Oscar Health by 3.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 45,022 shares of the company’s stock worth $295,000 after purchasing an additional 1,651 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Oscar Health by 0.8% during the third quarter. Rhumbline Advisers now owns 236,775 shares of the company’s stock worth $1,319,000 after purchasing an additional 1,832 shares during the last quarter. Hedge funds and other institutional investors own 75.70% of the company’s stock.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.